



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/30 (10/2001)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL Address to: Commissioner for Patents Box RCE Washington, DC 20231	Application Number	09/155,514
	Filing Date	November 17, 1998
	First Named Inventor	Mie Kainoh
	Art Unit	1644
	Examiner Name	R. Schwadron
	Attorney Docket Number	1102-98

RECEIVED
SEP 29 2002
TECH CENTER 1600/2808

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8,

1. Submission required under 37 CFR §1.114

a. ☐ Previously submitted

i. ☐ Consider the amendment(s)/reply under 37 CFR §1.116 previously filed on _____
(Any unentered amendment(s) referred to above will be entered).

ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____

iii. ☐ Other _____

b. ☒ Enclosed

i. ☒ Amendment/Reply

iii. ☐ Information Disclosure Statement (IDS)

ii. ☐ Affidavit(s)/Declaration(s)

iv. ☒ Other Ext. of Time Req., Amendment-Trans. Ltr.

2. Miscellaneous

a. ☐ Suspension of action on the above-identified application is requested under 37 CFR §1.103(c) for a period of _____ months (Period of suspension shall not exceed 3 months; Fee under 37 CFR §1.17(i) required)

b. ☐ Other _____

3. Fees The RCE fee under 37 CFR §1.17(e) is required by 37 CFR §1.114 when the RCE is filed.

a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 13-3405

i. ☐ RCE fee required under 37 CFR §1.17(e) | 09/18/2002 SZEWDIE1 00000015 09155514

ii. ☐ Extension of time fee (37 CFR §§1.136 and 1.17) | 01 FC:179

740.00 OP

iii. ☐ Other _____

b. ☒ Check in the amount of \$ 740. and \$920. enclosed

c. ☐ Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print / Type)

T. Daniel Christenbury

Registration No. (Attorney / Agent)

31,750

Signature

TDC

Date

11 SEP 2002

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark

Name (Print / Type)

T. Daniel Christenbury

Signature

TDC

Date

11 SEP 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.



Attorney Docket No.: 1102-98

TECH CENTER 1600/2900

SEP 23 2002

RECEIVED

In re Application of: Mie Kainoh et al.

Serial No.: 09/155,514

Filed: November 17, 1998

For: CHIMERIC PROTEINS, THEIR HETERODIMER COMPLEXES, AND PLATELET SUBSTITUTES

Box RCE
COMMISSIONER FOR PATENTS
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment in the above-identified application.

- Small entity status of this application under 37 CFR §1.9 and §1.27 has been established by a verified statement previously submitted.
- A verified statement to establish small entity status under 37 CFR §1.9 and §1.27 is enclosed.
- x No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)

(Col. 2) (Col. 3)

SMALL ENTITY

OTHER THAN
SMALL ENTITY

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PRE- VIOUSLY PAID FOR	PRESENT EXTRA
TOTAL	*28	-	** 64 =	0
INDEP.	* 1	-	*** 6 =	0
First presentation of multiple dependent claim				

	ADD'L FEE
RATE	
x 9=	\$
x42=	\$
+140=	\$

OR

	ADD'L FEE
RATE	
x18=	\$
x84=	\$
+280=	\$

TOTAL ADDITIONAL FEE \$0 OR \$_____

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.


— Please charge my Deposit Account No. 13-3405 in the amount of \$ _____.
A duplicate copy of this sheet is enclosed.

— A check in the amount of \$ _____ is attached.

x The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 13-3405. A duplicate copy of this sheet is enclosed.

x Any filing fees under 37 CFR §1.16 for the presentation of extra claims.

x Any patent application processing fees under 37 CFR §1.17 with the exception of the Issue Fee which we intend to pay by check.



T. Daniel Christenbury
Reg. No. 31,750
Attorney for Applicant(s)

TDC:dh
(215)563-1810



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1644
Examiner : R. Schwadron
Serial No. : 09/155,514
Filed : November 17, 1998
Inventors : Mie Kainoh
 : Toshiaki Tanaka
Title : CHIMERIC PROTEINS, THEIR
 : HETERODIMER COMPLEXES,
 : AND PLATELET SUBSTITUTES



22469

PATENT TRADEMARK OFFICE

Confirmation No.: 8751
Docket: 1102-98

Dated: September 11, 2002

TECH CENTER 1600/2900

SEP 23 2002

29/f
RECEIVED

AMENDMENT AND ARGUMENT

BOX RCE
Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Official Action dated March 26, 2002, Applicants amend as follows:

Marked-Up Version Showing Changes Made to the Specification

Please replace the paragraph bridging pages 11 and 12 with the following:

A chimeric protein consisting of the α chain of an integrin and the heavy chain or light chain of an immunoglobulin refers to a molecule in which the extracellular region of the α chain of an integrin is bound to the constant region of the heavy chain or light chain contained in an immunoglobulin. In this case, a chimeric protein in which the N terminus side of the protein is an integrin molecule and then connected to an immunoglobulin molecule side by side is preferable. A chimeric protein consisting of the β chain of an integrin and the heavy chain or light chain of an immunoglobulin refers to a molecule in which the extracellular region of the β chain of an integrin is bound to the constant region